ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: INFO17-TH

The LAPIS Trial: A Biomarker-Guided Implementation of Kidney-Sparing Care Measures to Prevent AKI in Sepsis Patients

Session Information

  • Informational Posters - I
    November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury


  • Kellum, John A., University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Ronco, Claudio, University of Padova, IRRIV, San Bortolo Hospital, Vicenza, Italy
  • Guzzi, Louis Michael, Florida Hospital, Longwood, Florida, United States
  • Heskia, Fabienne, bioMérieux, Marcy l'Etoile, France
  • Toback, Seth, bioMérieux, Marcy l'Etoile, France

Sepsis associated acute kidney injury (SA-AKI) increases the risk of morbidity and mortality. A novel biomarker [TIMP-2/IGFBP-7] (NephroCheckÒ) is available to aid in the clinical evaluation of critically ill patients who are at increased risk for developing AKI.

Subjects and methods
LAPIS is a randomized, controlled, multicenter trial of adults with a clinical diagnosis of sepsis at risk of developing AKI. Sites in the USA and Europe will participate to the study, enrolling approximately 750 subjects.

Enrollment and testing:
Subjects will be randomized 1:1 into 1 of 2 arms:
Control arm: subjects will be assessed for AKI based on clinical criteria and standard of care (SOC) assessments. NephroCheck testing will be performed with results masked to the site.
Intervention arm: subjects will be assessed for AKI based on clinical criteria plus three NephroCheck tests during the first day following the clinical diagnosis of sepsis.

Patient management:
Subjects randomized to the Control arm will be treated according to the attending clinician’s clinical judgment and the site’s SOC for treating sepsis patients; all interventions will be recorded.

Subjects randomized to the Intervention arm will be treated based on test results:
Subjects with all three negative NephroCheck Test results will receive a Test Negative Sepsis Bundle (TNSB) which allows for less intensive monitoring and faster de-escalation of care than SOC.
Subjects with any positive NephroCheck Test result will receive a Kidney-Sparing Sepsis Bundle (KSSB) with 3 levels of care possible depending on the test results. Interventions are based upon the KDIGO Guidelines.

The primary endpoint will be a composite of death, dialysis or progression of 2 stages of AKI (stage 0 to stage 2 and stage 1 to stage 3) within 96 hours. We will assess the impact of the NephroCheck-guided KSSB and TNSB on AKI severity healthcare utilization. Additional endpoints will include hospital and ICU length of stay, 30-day readmission rates and other health-economic endpoints. The study is scheduled to begin enrollment in early 2020.


  • bioMeriuex Inc.